Primary prevention strategies, such as vaccinations at the age extremes, in neonates and elderly individuals, demonstrate a challenge to health professionals and public health specialists. The aspects of the differentiation and maturation of the adaptive immune system, the functional implications of immunological immaturity or immunosenescence and its impact on vaccine immunogenicity and efficacy will be highlighted in this review. Several approaches have been undertaken to promote Th1 responses in neonates and to enhance immune functions in elderly, such as conjugation to carrier proteins, addition of adjuvants, concomitant vaccination with other vaccines, change in antigen concentrations or dose intervals or use of different administration routes. Also, early protection by maternal vaccination seems to be beneficial in neonates. However, it also appears necessary to think of other end points than antibody concentrations to assess vaccine efficacy in neonates or elderly, as also the cellular immune response may be impaired by the mechanisms of immaturity, underlying health conditions, immunosuppressive treatments or immunosenescence. Thus, lifespan vaccine programs should be implemented to all individuals on a population level not only to improve herd protection and to maintain protective antibody levels and immune memory, but also to cover all age groups, to protect unvaccinated elderly persons and to provide indirect protection for neonates and small infants.

Keywords:
Immunosenescence, Aging, T cells, B cells, Immunization , Vaccination, Thymus, Influenza, Neonates, Antibody
1.
Weiskopf D, Weinberger B, Grubeck-Loebenstein B: The aging of the immune system. Transpl Int 2009;22:1041-1050.
2.
Schönland SO, Zimmer JK, Lopez-Benitez CM, Widmann T, Ramin KD, Gornozy JJ, Weyand CM: Homeostatic control of T-cell generation in neonates. Blood 2003;102:1428-1434.
3.
Walker JC, Smolders MAJC, Gemen EFA, Antonius TAJ, Leuvenink J, de Vries E: Development of lymphocyte subpopulations in preterm infants. Scand J Immunol 2010;73:53-58.
4.
Zhang B, Ohtsuka Y, Fujii T, Baba H, Okada K, Shoji H, Nagata S, Shimizu T, Yamashiro Y: Immunological development of preterm infants in early infancy. Clin Exp Immunol 2005;140:92-96.
5.
Gibbons DL, Haque SFY, Silberzahn T, Hamilton K, Langford C, Ellis P, Carr R, Hayday AC: Neonates harbor highly active γδ T cells with selective impairments in preterm infants. Eur J Immunol 2009;39:1794-1806.
6.
Lee HL, Hoeman CM, Hardaway JC, Guloglu EB, Ellis JS, Jain R, Divekar R, Tartar DM, Haymaker CL, Zaghouani H: Delayed maturation of an IL-12-producing dendritic cell subset explains the early Th2 bias in neonatal immunity. J Exp Med 2008;205:2269-2280.
7.
Ferrando-Martínez S, Ruiz-Mateos E, Hernández A, Gutiérrez E, Rodríguez-Méndez M, Ordoñez A, Leal M: Age-related deregulation of the naïve T cell homeostasis in elderly humans. Age 2011;33:197-207.
8.
Lazuardi L, Jenewein B, Wolf AM, Pfister G, Tzankov A, Grubcek-Loebenstein B: Age-related loss of naive T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. Immunology 2005;114:37-43.
9.
Heng TSP, Chidgey AP, Boyd RL: Getting back at nature: understanding thymic development and overcoming its atrophy. Curr Opin Pharmacol 2010;10:425-433.
10.
Siegrist CA, Aspinall R: B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009;9:185-194.
11.
Wood N, Siegrist CA: Neonatal immunization: where do we stand? Curr Opin Infect Dis 2011;24:190-195.
12.
Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M: IgG Placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012, in press.
13.
El Sayed N, el Gamal Y, Abbassy AA, Seoud I, Salama M, Kandeel A, Hossny E, Shawky A, Hussein HA, Pallansch MA, van der Avoort HG, Burton AH, Sreevatsava M, Malankar P, Wahdan MH, Sutter RW: Monovalent type 1 oral poliovirus vaccine in newborns. N Engl J Med 2008;359:1655-1665.
14.
Klein NP, Gans HA, Sung P, Yasukawa LL, Johnson J, Sarafanov A, Chumakov K, Hansen J, Black S, Dekker CL: Preterm infants' T cell responses to inactivated poliovirus vaccine. J Inf Dis 2010;201:214-222.
15.
Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, Moyer LA, Bell BP, Alter MJ; Advisory Committee on Immunization Practices (ACIP): A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendation of the Advisory Committee on Immunization Practices (ACIP) part 1 - immunization of infants, children, and adolescents. MMWR Recomm Rep 2005;54:1-31.
16.
Kaufmann SH, Hussey G, Lambert PH: New vaccines for tuberculosis. Lancet 2010;375:2110-2119.
17.
Poolman J, Borrow R: Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 2011;10:307-322.
18.
Ambrosino DM, Sood SK, Lee MC, Chen D, Collard HR, Bolon DL, Johnson C, Daum RS: IgG1, IgG2 and IgM responses to two Haemophilus influenzae type B conjugate vaccines in young infants. Pediatr Infect Dis J 1992;11:855-859.
19.
Eskola J, Kayhty H: Early immunization with conjugate vaccines. Vaccine 1998;16:1433-1438.
20.
Van den Biggelaar AHJ, Richmond PC, Pomat WS, Phuanukoonnon S, Nadal-Sims MA, Devitt CJ, Siba PM, Lehmann D, Holt PG: Neonatal pneumococcal conjugate vaccine immunization primes T cells for preferential Th2 cytokine expression: a randomized controlled trial in Papua New Guinea. Vaccine 2009;27:1340-1347.
21.
Slack MH, Schapira D, Thwaites RJ, Burrage M, Southern J, Andrews N, Borrow R, Goldblatt D, Miller E: Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type B conjugate vaccines. J Infect Dis 2011;184:1617-1620.
22.
Brynjolfsson SF, Bjarnarson SP, Mori E, Del Giudice G, Jonsdottir I: Concomitant administration of Mycobacterium bovis BCG with the meningococcal C conjugate vaccine to neonatal mice enhances antibody response and protective efficacy. Clin Vacc Immunol 2011;18:1936-1942.
23.
Omon E, Damase-Michel C, Hurault-Delarue C, Lacroix I, Montastruc JL, Oustric S, Escourrou B: Non-adjuvanted 2009 influenza A(H1N1)v vaccine in pregnant women: the results of a French prospective descriptive study. Vaccine 2011;29:9649-9654.
24.
Vermeulen F, Verscheure V, Damis E, Vermeylen D, Leloux G, Dirix V, Locht C, Mascart F: Cellular immune response of preterm infants after vaccination with whole-cell or acellular pertussis vaccines. Clin Vacc Immunol 2010;17:258-262.
25.
Murphy TV, Slade BA, Broder KR, Kretsinger K, Tiwari T, Joyce MP, Iskander JK, Brown K, Moran JS: Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants. MMWR 2008;57:1-47.
26.
Michel JP: Update vaccine guidelines for aging and aged citizens of Europe. Expert Rev Vaccines 2010;9:7-10.
27.
Chen WH, Kozlovsky BF, Effros RB, Grubeck-Loebenstein B, Edelman R, Sztein MB: Vaccination in the elderly: an immunological perspective. Trends Immunol 2009;30:351-359.
28.
Sasaki S, Sullivan M, Narvaez CF, Holmes TH, Furman D, Zheng NY, Nishtala M, Wrammert J, Smith K, James JA, Dekker CL, Davis MM, Wilson PC, Greenberg HB, He XS: Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest 2011;121:3109-3119.
29.
Blomberg BB, Frasca D: Quantity, not quality, of antibody response decreased in the elderly. J Clin Invest 2011;121:2981-2983.
30.
Wilkinson TM, Li CFK, Chui CSC, Huang AKY, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, Staples KJ, Dong T, Douek DC, McMichael AJ, Xu XN: Preexisting influenza-specifc CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012;18:274-281.
31.
Trzonkowski P, Mysliwska J, Pawelec G, Mysliwski A: From bench to bedside and back: the SENIEUR protocol and the efficacy of influenza vaccination in the elderly. Biogerontol 2009;10:83-94.
32.
Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferronin E, Thorning S, Thomas RE: Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010;17:CD004876.
33.
Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V: Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005;366:1165-1174.
34.
Poland GA: Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines. Clin Infect Dis 2010;50:S54-S53.
35.
The Joint Committee on Vaccination and Immunisation: JCVI statement on discontinuation of the routine pneumococcal vaccination programme for adults aged 65 years and older. 16 March 2011; www.dh.gov.uk.
36.
Jelenik Z, Keller M, Briggs B, Günther G, Haglund M, Hudeckova H, Jilkova E, Mickiene A, Sandell B, Steffen B, Strle F: Tick-borne encephalitis and golden agers: position paper of the International Scientific Working Group on Tick-borne encephalitis (ISW-TBE). Wien Med Wochenschr 2010;160:247-251.
37.
Karhunen M, Leino T, Salo H, Devidkin I, Kilpi T, Auranen K: Modelling the impact of varicella vaccination on varicella and zoster. Epidemiol Infect 2010;138:469-481.
38.
Vossen MT, Gent MR, Weel JF, de Jong MD, van Lier RA, Kuijpers TW: Development of virus-specific CD4+ T cells on reexposure to Varicella-Zoster virus. J Infect Dis 2004;190:72-82.
39.
Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL, Shingles Prevention Study Group: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-2284.
40.
Sullivan SJ, Jacobson R, Poland GA: Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine. Expert Rev Vaccines 2010;9:1127-1133.
41.
Ansaldi F, Durando P, Icardi G: Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement. Expert Opin Biol Ther 2011;11:415-427.
42.
Arulanandam B, Mittler J, Lee W, O'Toole M, Metzger D: Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines. J Immunol 2000;164:3698-3704.
43.
Rosenkrands I, Vingsbo-Lundberg C, Bundgaard TJ, Lindenstrom T, Enouf V, van der Werf S, Andersn P, Agger EM: Enhanced humoral and cell-mediated immune responses after immunization with trivalent infuenza vaccine adjuvanted with cationic liposomes. Vaccine 2011;29:6283-6291.
44.
O'Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G: MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines 2011;10:447-462.
45.
Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, Baehner F, Borkowski A, Tsai TF, Clemens R: Oil-in- water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011;365:1406-1416.
46.
Moser C, Amacker M, Zurbriggen R: Influenza virosomes as a vaccine adjuvant and carrier system. Expert Rev Vaccines 2011;10:437-446.
47.
Nichol KL: Live attenuated influenza virus vaccines: new options for prevention of influenza. Vaccine 2001;19:4373-4377.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.